Epizódjegyzetek
In this episode, Prof. Robin Foà, Prof. Filippo Milano and Prof. Sabina Chiaretti explore the first results of a worldwide randomized phase 3 trial that challenges a long-standing paradigm in adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL): the necessity of frontline chemotherapy. The discussion focuses on a direct comparison between a fully chemo-free strategy—combining Ponatinib and Blinatumomab—and the conventional standard of care based on Imatinib plus chemotherapy.
The trial enrolled 236 patients with no upper age limit and introduced age-adapted dosing of Ponatinib…
Weboldal: podcasters.spotify.com

